Literature DB >> 12650387

Determinants of HMO formulary adoption decisions.

David Dranove1, Edward F X Hughes, Mark Shanley.   

Abstract

OBJECTIVE: To identify economic and organizational characteristics that affect the likelihood that health maintenance organizations (HMOs) include new drugs on their formularies. DATA SOURCES: We administered an original survey to directors of pharmacy at 75 HMOs, of which 41 returned usable responses. We obtained drug-specific data from an industry trade journal. STUDY
DESIGN: We performed multivariate logistic regression analysis, adjusting for fixed-drug effects and random-HMO effects. We used factor analysis to limit the number of predictors. DATA COLLECTION
METHODS: We held initial focus groups to help with survey design. We administered the survey in two waves. We asked respondents to report on seven popular new drugs, and to describe a variety of HMO organizational characteristics. PRINCIPAL
FINDINGS: Several HMO organizational characteristics, including nonprofit status, the incentives facing the director of the pharmacy, size and make-up of the pharmacy and therapeutics committee, and relationships with drugs makers, all affect formulary adoption.
CONCLUSIONS: There are many organizational factors that may cause HMOs to make different formulary adoption decisions for certain prescription drugs.

Mesh:

Year:  2003        PMID: 12650387      PMCID: PMC1360880          DOI: 10.1111/1475-6773.t01-1-00111

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  4 in total

1.  Implementation issues in disease management programs: a pharmaceutical company perspective.

Authors:  R A Browne
Journal:  Med Interface       Date:  1995-04

2.  Managed care pharmacy, socioeconomic assessments and drug adoption decisions.

Authors:  A Lyles; B R Luce; A M Rentz
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

3.  Hospital drug formularies and use of hospital services.

Authors:  F A Sloan; G S Gordon; D L Cocks
Journal:  Med Care       Date:  1993-10       Impact factor: 2.983

4.  Pharmacy benefit management companies.

Authors:  R Taniguchi
Journal:  Am J Health Syst Pharm       Date:  1995-09-01       Impact factor: 2.637

  4 in total
  6 in total

1.  Transparency in evidence evaluation and formulary decision-making: from conceptual development to real-world implementation.

Authors:  Bonnie B Dean; Kelly J Ko; Jennifer S Graff; A Russell Localio; Rolin Wade; Robert W Dubois
Journal:  P T       Date:  2013-08

2.  Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.

Authors:  Dominic Hodgkin; Constance M Horgan; Timothy B Creedon; Elizabeth L Merrick; Maureen T Stewart
Journal:  J Ment Health Policy Econ       Date:  2015-12

3.  Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.

Authors:  Dominic Hodgkin; Constance M Horgan; Amity E Quinn; Elizabeth L Merrick; Maureen T Stewart; Laurel K Leslie
Journal:  Clin Ther       Date:  2014-11-14       Impact factor: 3.393

4.  Methodological reporting in qualitative, quantitative, and mixed methods health services research articles.

Authors:  Jennifer P Wisdom; Mary A Cavaleri; Anthony J Onwuegbuzie; Carla A Green
Journal:  Health Serv Res       Date:  2011-11-08       Impact factor: 3.402

5.  Selection of medicines in Chilean public hospitals: an exploratory study.

Authors:  Juan F Collao; Felicity Smith; Nick Barber
Journal:  BMC Health Serv Res       Date:  2013-01-07       Impact factor: 2.655

Review 6.  Contextual Factors Influencing Cost and Quality Decisions in Health and Care: A Structured Evidence Review and Narrative Synthesis.

Authors:  Iestyn Williams; Hilary Brown; Paul Healy
Journal:  Int J Health Policy Manag       Date:  2018-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.